DMKJ
VRDN icon

David M. Knott Jr’s Viridian Therapeutics VRDN Stock Holding History

David M. Knott Jr’s Portfolio VRDN Stock Details VRDN Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$3.32M Hold
181,000
– – 1.76% 17
2026
Q1 		$3.54M Buy
181,000
+36,000
+25% +$1.07M 2.11% 14
2025
Q4 		$4.51M Buy
145,000
+28,426
+24% +$780K 2.09% 11
2025
Q3 		$2.52M Buy
116,574
+25,091
+27% +$453K 1.01% 18
2025
Q2 		$1.28M Buy
91,483
+61,483
+205% +$834K 0.58% 27
2025
Q1 		$404K Buy
30,000
+5,000
+20% +$85.2K 0.19% 51
2024
Q4 		$479K Buy
+25,000
New +$544K 0.17% 47

Other funds holding VRDN

Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
BG
Bellevue Group Kuesnacht, Switzerland $4.75B AUM 68.58% 1-Year Est. Return
PBA
Paradigm Biocapital Advisors New York $5.34B AUM 380.18% 1-Year Est. Return
KCM
Kynam Capital Management Princeton, New Jersey $1.81B AUM 192.15% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $999B AUM 46.22% 1-Year Est. Return
FFM
Fairmount Funds Management West Conshohocken, Pennsylvania $1.51B AUM 546.08% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
DTC
Deep Track Capital Greenwich, Connecticut $6.87B AUM 205.24% 1-Year Est. Return

David M. Knott Jr's VRDN Position: Q2 2026 in Review

David M. Knott Jr held its Viridian Therapeutics (VRDN) position steady in Q2 2026 at 181,000 shares worth $3.32M. The position accounts for 1.76% of the portfolio, ranked #17.

David M. Knott Jr first reported a position in VRDN in Q4 2024 and has held it in 7 quarters since. The position peaked at $4.51M in Q4 2025. 212 funds tracked by Wall St. Rank hold VRDN as of Q2 2026.

  • David M. Knott Jr held 181,000 shares of Viridian Therapeutics worth $3.32M as of Q2 2026.
  • David M. Knott Jr left its Viridian Therapeutics share count unchanged in Q2 2026.
  • Viridian Therapeutics made up 1.76% of David M. Knott Jr's portfolio in Q2 2026, its #17 holding.
  • David M. Knott Jr first reported a position in Viridian Therapeutics in Q4 2024 and has held it in 7 quarters since.
  • David M. Knott Jr's Viridian Therapeutics position peaked at $4.51M in Q4 2025.
  • 212 funds tracked by Wall St. Rank held Viridian Therapeutics as of Q2 2026.

Based on David M. Knott Jr's 13F filing for Q2 2026, filed 12 Aug 2026.